GlassScriptPhysician profile
Farnaz Mohammadi
NPI 1245420140
$4,778.63
in general payments reported to CMS, 2019-2025
34 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2021: $242 · 2022: $485 · 2023: $1,007 · 2024: $1,420 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,592 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,592.20 |
| Education | $184.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $491.43 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $408.28 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $407.22 | 2019-2025 | |
| Amgen INC. | $343.09 | 2019-2025 | Tavneos, Repatha |
| Astrazeneca Pharmaceuticals LP | $305.80 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $263.37 | 2023-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $235.85 | 2021-2025 | Jynarque |
| Vifor Pharma, INC. | $234.02 | 2021-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $219.43 | 2019-2025 | Rayaldee |
| Abiomed | $199.72 | 2024-2025 | Impella |
| Novo Nordisk INC | $168.91 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Aurinia Pharma U.S., INC. | $162.78 | 2022-2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.22 | 2024-2025 | Jardiance |
| Pfizer INC. | $151.31 | 2023-2024 | |
| Boston Scientific Corporation | $134.14 | 2023 | Watchman Flx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $128.15 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $113.81 | 2025 | Keveyis |
| Baxter Healthcare | $112.01 | 2022-2023 | Renal - Extraneal Solution |
| Renalytix Ai, INC. | $84.95 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Alexion Pharmaceuticals, INC. | $84.77 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $76.55 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Ardelyx, INC. | $54.90 | 2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $42.22 | 2023-2025 | Velphoro, Velphoro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31.67 | 2019 | |
| Daiichi Sankyo INC. | $23.20 | 2023 | Injectafer |
| Nxstage Medical, INC. | $20.61 | 2019 | |
| Shire North American Group INC | $19.69 | 2019 | |
| Shield Therapeutics INC | $17.75 | 2023 | Accrufer |
| Horizon Therapeutics Plc | $17.04 | 2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $16.74 | 2023 | Purified Cortrophin Gel |
| Madrigal Pharmaceuticals | $16.15 | 2025 | Rezdiffra |
| Akebia Therapeutics INC | $15.10 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.38 | 2019 | |
| Travere Therapeutics, INC. | $5.37 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farnaz Mohammadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.